continuing the culture for about a further 1 to 4 days; and

- 3) recovering the dendritic cells formed.
- 15. (New) A method according to Claim 14 wherein step 1) is carried out for 5 days and step 2) for 2 days.
- 16. (New) A method according to Claim 14 wherein the interleukin is interleukin-4 or interleukin-13.
- 17. (New) A method according to Claim 14 wherein the inflammatory mediator is tumor necrosis factor alpha (TNF- α).
- 18. (New) A method according to Claim 14 wherein the inflammatory mediator is tumor necrosis factor alpha (TNF-α) and prostaglandin E2 (PGE2).
- 19. (New) A method according to Claim 14 wherein the mononuclear cells are obtained by cytapheresis after mobilization by chemotherapy and/or with at least one cell growth factor.
- 20. (New) A method according to Claim 14 wherein GM-CSF, interleukin and TNF-α are each used at a rate of 1 to 1000 ng/ml of medium.
- 21. (New) A method according to Claim 14 wherein human albumin is used at a rate of 1 to 2% w/v of medium.
- 22. (New) A method according to Claim 14 wherein human albumin is used at a rate of 2% w/v of medium.
- 23. (New) A method of immunotherapeutic treatment, comprising:
- 1) obtaining mononuclear cells from a patient to be treated by cytapheresis after mobilization by chemotherapy and/or with a cell growth factor and optionally

703 412-1155

freezing/thawing;

- 2) cultivating, for 4 to 6 days, mononuclear cells derived from cytapheresis after mobilization, in a serum-free medium supplemented with human albumin, in the presence of a granulocyte-macrophage colony stimulating factor (GM-CSF) and an interleukin (IL) that blocks differentiation towards the macrophagic pathway;
- 3) adding TNF- α and optionally an inflammatory mediator to the culture medium and continuing the culture for about a further 1 to 4 days while activating them with specific antigens;
- 4) recovering the dendritic cells formed and activated in this way; and
- 5) reinjecting said dendritic cells into said patient.
- 24. (New) A method according to Claim 23 wherein the dendritic cells are frozen/thawed before being reinjected into said patient.--

<u>REMARKS</u>

The specification has been amended to correct minor typographical errors and omissions of an obvious nature.

The Claims have been amended to place them in a more prefered form for U.S. practice and to remove multiple dependencies.

No new matter would be added to this application by entry of the amendment. Upon entry of this amendment, Claims 14-24 will be active in the application.

Applicants also submit herewith a copy of the Search Report from the European